Menu
Not yet recruiting NCT05598359

TA-65 and Aging Associated Microvascular Dysfunction

No phase Interventional Telomere Shortening Aging Vascular Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: TA-65, Placebo.
Who it may be relevant to
Registry conditions: Telomere Shortening, Aging, Vascular Diseases. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.

Detailed description

The purpose of this clinical trial is to examine whether activation of autophagy with TA-65 which activates telomerase, improves microvascular function and blood pressure in an older population

Interventions

  • Dietary supplement TA-65
    TA-65 is a purified small molecule extracted from Astragalus root
  • Other Placebo
    Inactive formulation

Primary outcome measures

  • Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis [Time frame: 28 days]
Secondary outcome measures (1)
  • Systemic Blood Pressure [Time frame: 28 days]

Eligibility criteria

Inclusion criteria

  • Healthy Adults 18 - 35 and 65+ years of age
  • Subjects with clinical diagnosis of CAD

Exclusion criteria will include:

  • 36-64 years of age without clinical diagnosis of CAD
  • Self-reported habitual vigorous exercise (>20 min, 3 times per week, 1 yr)
  • Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)
  • Heart Failure
  • Renal Impairment
  • >3 Pre-existing Cardiovascular Risk Factors (healthy groups only)
  • Type 1 or type 2 diabetes
  • Uncontrolled hypertension
  • Current tobacco use or within last 6 months
  • BMI > 35
  • Hyperlipidemia
  • Hypercholesterolemia
  • Use of anti-coagulant drugs
  • Use of anti-platelet drugs
  • Erectile dysfunction medication in the past 6 months
  • Use of topical/non-topical steroids in last 6 months
  • Hormone replacement therapy (Post-Menopause or Gender Reassignment)
  • History of retinopathy
  • Documented neuromuscular disorders
  • Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
  • Pregnancy (young female subjects)
  • Allergy to lidocaine
  • Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months
  • Active COVID-19 or within the past 3 months

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Double blind
Primary purpose
Basic science

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05598359 · TA-65 and Vascular Aging

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗